This promotes tumorigenesis and development, manifesting as highly aggressive and metastatic characteristics with elevated tumor mutational burden, consistent with the aggressive phenotypes reported in SMARCA4-deficient tumors (e.g., non-small cell lung cancer, ovarian cancer). Here, SMARCA4 is linked to ovarian cancer.